Santosh Khanal

Santosh Khanal

Auto-generated profile, based on publicly available information

Santosh Khanal

Genomic Medicine Center, Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
CLCas LeMaster
Cas LeMaster
SPStephen H. Pierce
Stephen H. Pierce
EGEric Geanes
Eric Geanes
SKSantosh Khanal
Santosh Khanal
SEStaci S. Elliott
Staci S. Elliott
TBTodd Bradley
Todd Bradley
Human milk is essential for infant nutrition and immunity, providing protection against infections and other immune-mediated diseases during the lactation period and beyond in later childhood. Milk contains a broad range of bioactive factors such as nutrients, hormones, enzymes, immunoglobulins, growth factors, cytokines, and antimicrobial factors, as well as heterogeneous populations of maternal cells. The soluble and cellular components of milk are dynamic over time to meet the needs of the growing infant. In this study, we utilize systems-approaches to define and characterize 62 analytes of the soluble component, including immunoglobulin isotypes, as well as the cellular component of human milk during the first two weeks postpartum from 36 mothers. We identify soluble immune and growth factors that are dynamic over time and could be utilized to classify milk into different phenotypic groups. We identify 24 distinct populations of both epithelial and immune cells by single-cell transcriptome analysis of 128,016 human milk cells. We found that macrophage populations have shifting inflammatory profiles during the first two weeks of lactation. This analysis provides key insights into the soluble and cellular components of human milk and serves as a substantial resource for future studies of human milk.

22 September 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EFElizabeth Ross Fraley
Elizabeth Ross Fraley
CLCas LeMaster
Cas LeMaster
SKSantosh Khanal
Santosh Khanal
DBDithi Banerjee
Dithi Banerjee
TPTomi Pastinen
Tomi Pastinen
TBTodd Bradley
Todd Bradley
Determining the duration of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical for informing the timing of booster immunization. Many genetic and environmental factors could influence both the magnitude and persistence of the antibody response. Here, we showed that SARS-CoV-2 infection before vaccination and age affected the decay of antibody responses to the SARS-CoV-2 messenger RNA vaccine.

6 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
EFElizabeth Ross Fraley
Elizabeth Ross Fraley
SKSantosh Khanal
Santosh Khanal
SPStephen H. Pierce
Stephen H. Pierce
CLCas A. LeMaster
Cas A. LeMaster
RMRebecca McLennan
Rebecca McLennan
TBTodd Bradley
Todd Bradley
Understanding the B cell response to SARS-CoV-2 vaccines is a high priority. High-throughput sequencing of the B cell receptor (BCR) repertoire allows for dynamic characterization of B cell response. Here, we sequenced the BCR repertoire of individuals vaccinated by the Pfizer SARS-CoV-2 mRNA vaccine. We compared BCR repertoires of individuals with previous COVID-19 infection (seropositive) to individuals without previous infection (seronegative). We discovered that vaccine-induced expanded IgG clonotypes had shorter heavy-chain complementarity determining region 3 (HCDR3), and for seropositive individuals, these expanded clonotypes had higher somatic hypermutation (SHM) than seronegative individuals. We uncovered shared clonotypes present in multiple individuals, including 28 clonotypes present across all individuals. These 28 shared clonotypes had higher SHM and shorter HCDR3 lengths compared to the rest of the BCR repertoire. Shared clonotypes were present across both serotypes, indicating convergent evolution due to SARS-CoV-2 vaccination independent of prior viral exposure.